Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ANG-3070 (Ansornitinib) in Primary Glomerular Disease With Persistent Proteinuria
2021-006579-41Phase 2Terminated
- Sponsor
- Angion Biomedica Corp.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary glomerulonephritis and proteinuria comparing ANG-3070 with Placebo (2 arms). Started Feb 2022; status: terminated.
02
Drugs
ansornitinib
03
Conditions
primary glomerulonephritisproteinuria
Beyond the preview
Go deeper on 2021-006579-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006579-41.